SEC Company Response from TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686) (TEVA) — Jun 8, 2012
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686)
Date: June 8, 2012 · CIK: 0000818686 · Accession: 0000899140-12-000403
AI Filing Summary & Sentiment
File numbers found in text: 000-16174
Referenced dates: May 24, 2012
Show Raw Text
CORRESP
1
filename1.htm
t7947775.htm
VIA EDGAR
June 8, 2012
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Jim B. Rosenberg, Senior Assistant Chief Accountant
Division of Corporation Finance
Re:
Teva Pharmaceutical Industries Limited
Form 20-F for the Fiscal Year Ended December 31, 2011
Filed February 17, 2012
File No. 000-16174
Dear Mr. Rosenberg:
I refer to your letter dated May 24, 2012 to Eyal Desheh, Teva’s Chief Financial Officer, regarding Teva’s Form 20-F for the Fiscal Year Ended December 31, 2011. Teva is actively working on its responses to the comments of the Staff raised in the letter and expects to submit its responses by the end of next week.
Should any member of the Staff have any questions, please do not hesitate to call me at (212) 728-8592.
Very truly yours,
/s/ Jeffrey S. Hochman
Jeffrey S. Hochman
cc:
Mary Mast (SEC)
Frank Wyman (SEC)
Eyal Desheh (Teva)
Richard S. Egosi (Teva)
New York Washington Paris London Milan Rome Frankfurt Brussels
in alliance with Dickson Minto W.S., London and Edinburgh